Anti-TNFα drug levels in patients with rheumatoid arthritis and spondyloarthritis

Chen, 2015, Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis, Ann Rheum Dis, 74, 1, 10.1136/annrheumdis-2015-207978 Pascual-Salcedo, 2011, Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis, Rheumatology (Oxford), 50, 1445, 10.1093/rheumatology/ker124 Arstikyte, 2015, Influence of immunogenicity on the efficacy of long-term treatment with TNF α blockers in rheumatoid arthritis and spondyloarthritis patients, Biomed Res Int, 2015, 7, 10.1155/2015/604872 Terc, 2017, Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits, Immunol Res, 65, 172, 10.1007/s12026-016-8824-8 Rosas, 2020, Aspectos prácticos de la medición de los niveles de fármacos biológicos y de anticuerpos antifármaco en artritis reumatoide y espondiloartritis, Reumatol Clin, 16, 378, 10.1016/j.reuma.2018.09.006 den Broeder, 2018, Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts, Curr Opin Rheumatol, 30, 266, 10.1097/BOR.0000000000000487 Jurado, 2017, Predictive value of serum infliximab levels at induction phase in rheumatoid arthritis patients, Open Rheumatol J, 11, 75, 10.2174/1874312901711010075 Padilla-Martínez, 2019, Drug levels and antibodies against TNF-blockers in spondyloarthritis and rheumatoid arthritis are associated with the activity but they do not predict it, Curr Rheumatol Rev, 15, 329, 10.2174/1573397115666190708113601 Sanmarti, 2015, Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study, Ann Rheum Dis, 74, e42, 10.1136/annrheumdis-2015-207530 Pouw, 2015, Key findings towards optimising adalimumab treatment: the concentration-effect curve, Ann Rheum Dis, 74, 513, 10.1136/annrheumdis-2013-204172 Kneepkens, 2015, Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up, Ann Rheum Dis, 74, 1825, 10.1136/annrheumdis-2014-205213 Mould, 2015, The pharmacokinetics of biologics: a primer, Dig Dis, 33 Suppl 1, 61, 10.1159/000437077 Vogelzang, 2015, Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs, Ann Rheum Dis, 74, 474, 10.1136/annrheumdis-2014-206588 Ducourau, 2020, Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial, RMD Open, 6, 6, 10.1136/rmdopen-2019-001047 Hässler, 2020, Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: a prospective multicohort study of the ABIRISK consortium, PLoS Med, 17, 10.1371/journal.pmed.1003348